Andy Chi

878 total citations · 1 hit paper
9 papers, 579 citations indexed

About

Andy Chi is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Andy Chi has authored 9 papers receiving a total of 579 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pathology and Forensic Medicine, 4 papers in Oncology and 3 papers in Immunology. Recurrent topics in Andy Chi's work include Lymphoma Diagnosis and Treatment (6 papers), Viral-associated cancers and disorders (3 papers) and T-cell and Retrovirus Studies (2 papers). Andy Chi is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Viral-associated cancers and disorders (3 papers) and T-cell and Retrovirus Studies (2 papers). Andy Chi collaborates with scholars based in United States, Italy and Poland. Andy Chi's co-authors include Dirk Huebner, Edward Agura, Emily K. Larsen, Veronika Bachanová, Jan Walewski, Andy I. Chen, Auayporn Nademanee, Dzhelil Osmanov, Jerzy Hołowiecki and Craig H. Moskowitz and has published in prestigious journals such as The Lancet, Blood and Critical Reviews in Oncology/Hematology.

In The Last Decade

Andy Chi

8 papers receiving 571 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

2015 477 citations Craig H. Moskowitz, Auayporn Nademanee et al. The Lancet profile →

Peers

Countries citing papers authored by Andy Chi

Since Specialization

Citations

This map shows the geographic impact of Andy Chi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy Chi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy Chi more than expected).

Fields of papers citing papers by Andy Chi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andy Chi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy Chi. The network helps show where Andy Chi may publish in the future.

Co-authorship network of co-authors of Andy Chi

This figure shows the co-authorship network connecting the top 25 collaborators of Andy Chi. A scholar is included among the top collaborators of Andy Chi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andy Chi. Andy Chi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	DOD-BART: machine learning-based dose optimization design incorporating patient-level prognostic factors via Bayesian additive regression trees 2024 ·Journal of Biopharmaceutical Statistics ·(unknown), Rachael Liu, Jianchang Lin, Andy Chi, Simon Davies	1
2	Practical considerations of utilizing propensity score methods in clinical development using real-world and historical data 2020 ·Contemporary Clinical Trials ·Qing Li, Jianchang Lin, Andy Chi, Simon Davies	19
3	Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas 2016 ·Critical Reviews in Oncology/Hematology ·Pier Luigi Zinzani, Vijayveer Bonthapally, Dirk Huebner, Richard A. Lutes, Andy Chi, Stefano Pileri	34
4	Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas 2016 ·Critical Reviews in Oncology/Hematology ·Pier Luigi Zinzani, Vijayveer Bonthapally, Dirk Huebner, Richard A. Lutes, Andy Chi, Stefano Pileri	25
5	Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial breakdown → 2015 ·The Lancet ·Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi, Edward Agura, Jerzy Hołowiecki, Muneer H. Abidi, Andy I. Chen, Patrick J. Stiff, Alessandro M. Gianni, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanová, John Sweetenham, Anna Sureda, Dirk Huebner, Eric L. Sievers, Andy Chi, Emily K. Larsen, Naomi Hunder, Jan Walewski	477
6	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data 2015 ·Current Medical Research and Opinion ·Vijayveer Bonthapally, Eric Q. Wu, Alexander R. Macalalad, Hongbo Yang, Oluwatoyin Shonukan, Yi Liu, Andy Chi, Dirk Huebner	12
7	Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis 2015 ·Current Medical Research and Opinion ·Vijayveer Bonthapally, Hongbo Yang, Rajeev Ayyagari, (unknown), (unknown), Eric Q. Wu, Ashish Gautam, Andy Chi, Dirk Huebner	9
8	Surgical Reconstruction of Severe Forefoot Derangement in a Patient with Traumatically Acquired Contralateral Limb-length Discrepancy 2012 ·Journal of the American Podiatric Medical Association ·(unknown), (unknown), Rakesh Patel, Andy Chi, (unknown)	1
9	Activity of the Investigational Antibody–Drug Conjugate Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large-Cell Lymphoma: Comparisons with Meta-Analyses of Historical Control Chemotherapy Data 2011 ·Blood ·Antonio Gualberto, Andy Chi, Yi Liu	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact